Compare BMBL & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMBL | VALN |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.4M | 495.5M |
| IPO Year | 2021 | 2021 |
| Metric | BMBL | VALN |
|---|---|---|
| Price | $2.74 | $5.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 2 |
| Target Price | $4.46 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 2.8M | 26.9K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $965,658,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $93.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.54 | $4.75 |
| 52 Week High | $7.32 | $12.25 |
| Indicator | BMBL | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 42.88 | 64.67 |
| Support Level | $2.66 | $5.55 |
| Resistance Level | $3.21 | $6.69 |
| Average True Range (ATR) | 0.16 | 0.17 |
| MACD | -0.03 | 0.08 |
| Stochastic Oscillator | 23.62 | 71.51 |
Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company operates as one operating segment with revenue derived in the form of recurring subscriptions and in-app purchases. The company operates in USA, which derives maximum revenue; and Rest of the World.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.